Towards optimal treatment with growth hormone in short children and adolescents: Evidence and theses

Hormone Research in Paediatrics

Volumn 79, Issue 2, 2013, Pages 51-67

  Ranke, Michael B ^a,i   Lindberg, Anders ^b   Mullis, Primus E ^c   Geffner, Mitchell E ^d   Tanaka, Toshi ^e   Cutfield, Wayne S ^f   Tauber, Maïthé ^g   Dunger, David ^h  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b PFIZER INC   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Tanaka Growth Clinic   (Japan)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g HÔPITAL DES ENFANTS   (France)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cost effectiveness; Efficacy; Growth hormone treatment; Optimization

Indexed keywords

RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; GROWTH HORMONE;

ADOLESCENT DISEASE; ALGORITHM; BODY HEIGHT; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GROWTH; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; METABOLIC PARAMETERS; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PUBERTY; REVIEW; SHORT STATURE; THERAPY EFFECT; TREATMENT RESPONSE; ADOLESCENT; CHILD; DECISION MAKING; GROWTH DISORDER; HORMONAL THERAPY; MEDICATION COMPLIANCE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ALGORITHMS; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; MALE;

EID: 84874283828     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000347121     Document Type: Review

References (114)

1. Tattersall R: A history of growth hormone. Horm Res 1996; 46: 236-247.
2. Lindholm J: Growth hormone: historical notes. Pituitary 2006; 9: 5-10.
3. Raben MS: Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18: 901-903.
4. Richmond E, Rogol A: Current indications for growth hormone therapy for children and adolescents; in Hindmarsh PC (ed): Current Indications for Growth Hormone Therapy, ed 2, revised. Basel, Karger, 2010, vol 18, pp 92-108.
5. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M, European Society of Paediatric Endocrinology: Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005; 152: 165-170.
6. Allen DB: Clinical review: lessons learned from the hGH era. J Clin Endocrinol Metab 2011; 96: 3042-3047.
7. Juul A, Bernasconi S, Clayton PE, Kiess W, DeMuinck-Keizer Schrama S, Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE): European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm Res 2002; 58: 233-241.
8. Miller BS, Shulman DI, Shillington A, Harshaw Q, Wilson DM, Schwartz D, Kappy M, Bakker B, Wyatt D: Consensus and discordance in the management of growth hormone-treated patients: results of a knowledge, attitudes, beliefs, and practices survey. Int J Pediatr Endocrinol 2010; 2010: 891571.
9. Wit JM: Growth hormone therapy. Best Pract Res Clin Endocrinol Metab 2002; 16: 483-503.
10. Wit JM: Optimizing growth hormone therapy in growth hormone deficient children: what to do in the absence of hard evidence? Horm Res 2007; 68: 244-247.
11. Carel JC, Butler G: Safety of recombinant human growth hormone. Endocr Dev 2010; 18: 40-54.
12. Allen DB: Safety of growth hormone treatment of children with idiopathic short stature: the US experience. Horm Res Paediatr 2011; 76(suppl 3):45-47.
13. Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A: Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, the Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012; 97:E213-E217.
14. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J: Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012; 97: 416-425.
15. Ranke MB, Lindberg A: Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 2009; 19: 1-11.
16. Webb EA, Dattani MT: Diagnosis of growth hormone deficiency. Endocr Dev 2010; 18: 55-66.
17. Ranke MB: Growth hormone deficiency: diagnostic principles and practice; in Ranke MB, Mullis PE (eds): Diagnostics of Endocrine Function in Children and Adolescents, ed 4. Basel, Karger, 2011, pp 102-137.
18. Caliebe J, Martin DD, Ranke MB, Wit JM: The auxological and biochemical continuum of short children born small for gestational age (SGA) or with normal birth size (idiopathic short stature). Int J Pediatr Endocrinol 2010; 2010: 852967.
19. Wit JM: Definition and subcategorization of idiopathic short stature: between consensus and controversy. Horm Res Paediatr 2011; 76(suppl 3):3-6.
20. Wikland KA, Kriström B, Rosberg S, et al: Validated multivariate models predicting growth response to GH treatment in individual short children with a broad range in GH secretion capabilities. Pediatr Res 2000; 48: 475-484.
21. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B: Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010; 95: 167 -177.
22. Wilton P, Mattsson AF, Darendeliler F: Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr 2010; 157: 265-270.
23. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA: Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91: 3494 - 3498.
24. Wilton P: Adverse events reported in KIGGS; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics - 20 Years of KIGS. Basel, Karger, 2007, pp 432-441.
25. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J: Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SGA study. J Clin Endocrinol Metab 2012; 97: 416-425.
26. Rosenfeld RG, Cohen P, Robinson LL, Bercu BB, Clayton P, Hoffman AR, Radovick S, Saenger P, Savage MO, Wit JM: Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab 2012; 97: 68-72.
27. Biannual Report No. 17; Pfizer & Upjohn International Growth Study 2000 - ISSN-1102-9587;ISRN GHF-KIGS-R-17-SE.
28. Cohen P, Clemmons DR, Rosenfeld RG: Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000; 10: 297-305.
29. Gallagher EJ, LeRoith D: Minireview: IGF, insulin, and cancer. Endocrinology 2011; 152: 2546-2551.
30. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG, American Norditropin Study Group: Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007; 92: 2480-2486.
31. Baron J: Editorial: growth hormone therapy in childhood: titration versus weight-based dosing? J Clin Endocrinol Metab 2007; 92: 2436-2438.
32. Rosenfeld RG, Bakker B: Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocrine Pract 2008; 14: 143-154.
33. Kirk J: Improving adherence to GH therapy with an electronic device: first experience with Easypod. Pediatr Endocrinol Rev 2009; 6(suppl 4):549-552.
34. Cázares-Delgadillo J, Ganem-Rondero A, Kalia YN: Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance. Eur J Pharm Biopharm 2011; 78: 278-288.
35. Cutfield WS, Derraik JG, Gunn AJ, Reid K, Delany T, Robinson E, Hofman PL: Noncompliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011; 6:e16223.
36. Kapoor RR, Burke SA, Sparrow SE, Hughes IA, Dunger DB, Ong KK, Acerini CL: Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008; 93: 147-148.
37. Pawlikowska-Haddal A, Cohen P, Cook DM: How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children? Pituitary 2011; 15: 126-134.
38. Harris EK, Yasaka T: On the calculation of a 'reference change' for comparing two consecutive measurements. Clin Chem 1983; 29: 25-30.
39. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG: The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab 2001; 86: 5176-5183.
40. Ranke MB, Traunecker R, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Binder G: IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age. Horm Res 2005; 64: 68-76.
41. Haverkamp F, Gasteyger C: A review of biopsychosocial strategies to prevent and overcome early-recognized poor adherence in growth hormone therapy of children. J Med Econ 2011; 14: 448-457.
42. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M, European Society of Paediatric Endocrinology: Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005; 152: 165-710.
43. Frindik JP, Baptista J: Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Pediatrics 1999; 104: 1000-1004.
44. Bayley N, Pinneau SR: Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952; 40: 423-441.
45. Tobiume H, Kanzaki S, Hida S, Ono T, Moriwake T, Yamauchi S, Tanaka H, Seino Y: Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab 1997; 82: 2056-2061.
46. Hermanussen M, Cole J: The calculation of target height reconsidered. Horm Res 2003; 59: 180-183.
47. Rikken B, Massa GG, Wit JM: Final height in a large cohort of Dutch patients with growth hormone deficiency treated with growth hormone. Dutch Growth Hormone Working Group. Horm Res 1995; 43: 135-137.
48. Blethen SL, Baptista J, Kuntze J, Foley T, LaFranchi S, Johanson A: Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study Group. J Clin Endocrinol Metab 1997; 82: 418-420.
49. Reiter EO, Price DA, Wilton P, et al: Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006; 91: 2047-2054.
50. de Ridder MA, Stijnen T, Hokken-Koelega AC: Prediction of adult height in growth-hormone-treated children with growth hormone deficiency. J Clin Endocrinol Metab 2007; 92: 925-931.
51. de Ridder MA, Stijnen T, Hokken-Koelega AC: Prediction model for adult height of small for gestational age children at the start of growth hormone treatment. J Clin Endocrinol Metab 2008; 93: 477-83.
52. Kriström B, Dahlgren J, Niklasson A, Nierop AF, Albertsson-Wikland K: The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children. BMC Med Inform Decis Mak 2009; 9: 1.
53. Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO, KIGS International Board: Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res 2007; 68: 53-62.
54. Ranke MB, Price DA, Albertsson-Wikland K, Maes M, Lindberg A: Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Analysis of 195 patients of the Kabi Pharmacia International Growth Study. Horm Res 1997; 48: 62-71.
55. Ranke MB, Lindberg A, KIGS International Board: Prediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database). BMC Med Inform Decis Mak 2011; 11: 38.
56. Ranke MB, Lindberg A, KIGS International Board: Height at start, first-year growth response and cause of shortness at birth are major determinants of adult height outcomes of short children born small for gestational age and Silver-Russell syndrome treated with growth hormone: analysis of data from KIGS. Horm Res Paediatr 2010; 74: 259-266.
57. Ranke MB, Lindberg A, Ferrández Longás A, Darendeliler F, Albertsson-Wikland K, Dunger D, Cutfield WS, Tauber M, Wilton P, Wollmann HA, Reiter EO, KIGS International Board: Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res 2007; 61: 105-110.
58. Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta 1989; 52(Suppl):1-125.
59. Kastrup KW, Christiansen JS, Andersen JK, Orskov H: Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh) 1983; 104: 148-152.
60. Albertsson-Wikland K: The effect of human growth hormone injection frequency on linear growth rate. Acta Paediatr Scand Suppl 1987; 337: 110-116.
61. Albertsson-Wikland K, Westphal O, Westgren U: Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand 1986; 75: 89-97.
62. MacGillivray MH, Blethen SL, Buchlis JG, Clopper RR, Sandberg DE, Conboy TA: Current dosing of growth hormone in children with growth hormone deficiency: how physiologic? Pediatrics 1998; 102: 527-530.
63. Merriam GR, Wachter KW, Ma N, Liu L: Synchronization of hormonal time series: analytical approaches. Acta Paediatr Scand Suppl 1991; 372: 63-68.
64. Martha PM Jr, Gorman KM, Blizzard RM, Rogol AD, Veldhuis JD: Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab 1992; 74: 336-344.
65. Albertsson-Wikland K, Rosberg S, Karlberg J, Growth T: Analysis of 24-hour growth hormone profiles in healthy boys and girls of normal stature: relation to puberty. J Clin Endocrinol Metab 1994; 78: 1195-1201.
66. Veldhuis JD: Neuroendocrine control of pulsatile growth hormone release in the human: relationship with gender. Growth Horm IGF Res 1998; 8(Suppl B):49-59.
67. Veldhuis JD, Roemmich JN, Rogol AD: Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females - a general clinical research centre-based study. J Clin Endocrinol Metab 2000; 85: 2385-2394.
68. Tanaka T: Global situation of growth hormone treatment in GHD children. Clin Pediatr Endocrinol 1990; 8(suppl 13):59-65.
69. Root AW, Kemp SF, Rundle AC, Dana K, Attie KM: Effect of long-term recombinant growth hormone therapy in children - the National Cooperative Growth Study, USA, 1985-1994. J Pediatr Endocrinol Metab 1998; 11: 403-412.
70. Juul A, Bernasconi S, Clayton PE, Kiess W, DeMuinck-Keizer Schrama S, Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE): European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm Res 2002; 58: 233-241.
71. Ranke MB, Reiter EO, Price DA: Idiopathic growth hormone deficiency in KIGS: selected aspects; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics - 20 years of KIGS. Basel, Karger, 2007, pp 116-135.
72. Lindberg A, Ranke MB: Data analyses within KIGS; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics - 20 Years of KIGS. Basel, Karger, 2007, pp 23-28.
73. Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul A, Kriström B, Tapanainen P, Aberg V: A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr 2011; 75: 335-345.
74. Martin DD, Wit JM, Hochberg Z, Sävendahl L, van Rijn RR, Fricke O, Cameron N, Caliebe J, Hertel T, Kiepe D, Albertsson-Wikland K, Thodberg HH, Binder G, Ranke MB: The use of bone age in clinical practice - part 1. Horm Res Paediatr 2011; 76: 1-9.
75. Martin DD, Wit JM, Hochberg Z, van Rijn RR, Fricke O, Weather G, Cameron N, Hertel T, Wudy SA, Butler G, Thodberg HH, Binder G, Ranke MB: The use of bone age in clinical practice - part 2. Horm Res Paediatr 2011; 76: 10-16.
76. Preece MA: The assessment of growth; in Ranke MB, Gunnarsson R (eds): Progress in Growth Hormone Therapy - 5 Years of KIGS. Mannheim, J&J Verlag, 1994, pp 10-36.
77. Marshall WA: Evaluation of growth rate in height over periods of less than one year. Arch Dis Child 1971; 46: 414-420.
78. Kriström B, Karlberg J, Albertsson-Wikland K: Prediction of the growth response of short prepubertal children treated with growth hormone. Swedish Paediatric Study Group for GH Treatment. Acta Paediatr 1995; 84: 51-57.
79. Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG: Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008; 93: 352-357.
80. Ranke MB, Lindberg A, KIGS International Board: Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010; 95: 1229-1237.
81. Blethen SL, Compton P, Lippe BM, Rosenfeld RG, August GP, Johanson A: Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab 1993; 76: 574-579.
82. Ranke MB, Guilbaud O, Lindberg A, Cole T: Prediction of the growth response in children with various growth disorders treated with growth hormone: analyses of data from the Kabi Pharmacia International Growth Study. International Board of the Kabi Pharmacia International Growth Study. Acta Paediatr Suppl 1993; 82(suppl) 391: 82-88.
83. Ranke MB, Lindberg A: Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 2009; 19: 1-11.
84. Schönau E, Westermann F, Rauch F, Stabrey A, Wassmer G, Keller E, Brämswig J, Blum WF, German Lilly Growth Response Study Group: A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol 2001; 144: 13-20.
85. Wikland KA, Kriström B, Rosberg S, Svensson B, Nierop AF: Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res 2000; 48: 475-484.
86. De Ridder MA, Stijnen T, Hokken-Koelega AC: Validation and calibration of the Kabi Pharmacia International Growth Study prediction model for children with idiopathic growth hormone deficiency. J Clin Endocrinol Metab 2003; 88: 1223-1227.
87. Dahlgren J, Kriström B, Niklasson A, Nierop AF, Rosberg S, Albertsson-Wikland K: Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. BMC Med Inform Decis Mak 2007; 7: 40.
88. Land C, Blum WF, Shavrikova E, Kloeckner K, Stabrey A, Schoenau E: Predicting the growth response to growth hormone (GH) treatment in prepubertal and pubertal children with isolated GH deficiency - model validation in an observational setting (GeNeSIS). J Pediatr Endocrinol Metab 2007; 20: 685-693.
89. Kriström B, Dahlgren J, Niklasson A, Nierop AF, Albertsson-Wikland K: The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children. BMC Med Inform Decis Mak 2009; 9: 1.
90. Wit JM, Kiess W, Mullis P: Genetic evaluation of short stature. Best Pract Res Clin Endocrinol Metab 2011; 25: 1-17.
91. Ranke MB, Lindberg A, Brosz M, Kaspers S, Loftus J, Wollmann H, Koltowska-Haggstrom M, Roelants M: Accurate long-term prediction of height during the first four years of growth hormone (GH) treatment in prepubertal children with growth hormone deficiency (GHD) or Turner syndrome (TS). Horm Res Paediatr 2012; 78: 8-17.
92. Kriström B, Jansson C, Rosberg S, Albertsson-Wikland K: Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGFbinding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment. J Clin Endocrinol Metab 1997; 82: 2889-2898.
93. Schwarze CP, Wollmann HA, Binder G, Ranke MB: Short-term increments of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. predict the growth response to growth hormone (GH) therapy in GH-sensitive children. Acta Paediatr 1999(Suppl); 88: 200-208.
94. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP, Wollmann HA: Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. Horm Res 2001; 55: 115-124.
95. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG; American Norditropin Study Group: Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007; 92: 2480-2486.
96. Clemmons DR: Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011; 57: 555-559.
97. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Müller J, Skakkebaek NE: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 2534-2542.
98. Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG, American Norditropin Study Group: Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGFbased dosing study of short children. J Clin Endocrinol Metab 2010; 95: 2089-2098.
99. Ranke MB: Insulin-like growth factor 1 levels in patients within the KIGS database; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics -20 Years of KIGS. Basel, Karger, 2007, pp 83-92.
100. Kriström B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K: Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab 2009; 94: 483-490.
101. Jung H, Land C, Nicolay C, De Schepper J, Blum WF, Schönau E: Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study. Eur J Endocrinol 2009; 160: 149-156
102. Largo RH, Gasser T, Prader A, et al: Analysis of the adolescent growth spurt using smoothing spline functions. Ann Hum Biol 1978; 5: 421-434.
103. Martin DD, Hauspie RC, Ranke MB: Total pubertal growth and markers of puberty onset in adolescents with GHD: comparison between mathematical growth analysis and pubertal staging methods. Horm Res 2005; 63: 95-101.
104. Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M, Mauras N, Bowers CY: Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 2005; 26: 114-146.
105. Price DA, Jönsson P: Induction of puberty with sex steroids: a description of clinical practice recorded in KIGS (Pharmacia & Upjohn International Growth Database). Biannual Report 1996, 2, N14.
106. Kiess W, Conways G, Ritzen M, et al: Induction of puberty in the hypogonadal girls -practices and attitudes of pediatric endocrinologists in Europe. Horm Res 2002; 57: 66-71.
107. MacGillivray MH: Induction of puberty in hypogonadal children. J Pediatr Endocrinol Metab 2004; 4(suppl):1277-1287.
108. Bourguignon JP: Linear growth as a function of age at onset of puberty and sex steroid dosage: the therapeutic implications. Endocr Rev 1988; 9: 467-488.
109. Ranke MB, Lindberg A: Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review. Horm Res Paediatr 2011; 75: 423-432.
110. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J: High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 2000; 85: 3653-3660.
111. Carel JC: Can we increase adolescent growth? Eur J Endocrinol 2004; 151:U101-U108.
112. Lee PA, Houk CP: Gonadotropin-releasing hormone analogue therapy for central precocious puberty and other childhood disorders affecting growth and puberty. Treat Endocrinol 2006; 5: 287-296.
113. Tanaka T: Sufficiently long-term treatment with combined growth hormone and gonadotropin-releasing hormone analog can improve adult height in short children with isolated growth hormone deficiency (GHD) and in non-GHD short children. Pediatr Endocrinol Rev 2007; 5: 471-481.
114. Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K: Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebocontrolled, multicentre trial for one to three years. J Clin Endocrinol Metab 2008; 93: 823-831.